Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD ...

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus ...